Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality-Reference-Cited by-同舟云学术

Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality

Published:2023-10-25 Issue:1 Volume:25 Page:1-5
ISSN:1618-7598
Container-title:The European Journal of Health Economics
language:en
Short-container-title:Eur J Health Econ

Author:

Capuozzo Maurizio^ORCID,Celotto Venere,Zovi Andrea^ORCID,Langella Roberto,Ferrara Francesco^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Link

https://link.springer.com/content/pdf/10.1007/s10198-023-01640-4.pdf

Reference19 articles.

1. Vogler, S., Vitry, A., Babar, Z.U.: Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 17(1), 39–47 (2016). https://doi.org/10.1016/S1470-2045(15)00449-0

2. Pauwels, K., Huys, I., Vogler, S., Casteels, M., Simoens, S.: Managed entry agreements for oncology drugs: lessons from the european experience to inform the future. Front. Pharmacol. 4(8), 171 (2017). https://doi.org/10.3389/fphar.2017.00171

3. Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osińska, B., Herholz, H., Wendykowska, K., Laius, O., Jan, S., Sermet, C., Zara, C., Kalaba, M., Gustafsson, R., Garuolienè, K., Haycox, A., Garattini, S., Gustafsson, L.L.: Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv. Res. 7(10), 153 (2010). https://doi.org/10.1186/1472-6963-10-153

4. Ciulla, M., Marinelli, L., Di Biase, G., Cacciatore, I., Santoleri, F., Costantini, A., Dimmito, M.P., Di Stefano, A.: Healthcare systems across Europe and the US: The managed entry agreements experience. Healthcare (Basel). 11(3), 447 (2023). https://doi.org/10.3390/healthcare11030447

5. Dabbous, M., Chachoua, L., Caban, A., Toumi, M.: Managed entry agreements: policy analysis from the European perspective. Value Health. 23(4), 425–433 (2020). https://doi.org/10.1016/j.jval.2019.12.008

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The challenge of antimicrobial resistance (AMR): current status and future prospects;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-25

2. The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company;Journal of Cancer Policy;2024-06

3. Improving the prescriptive appropriateness of vitamin D: The Italian experience;Nutrition Clinique et Métabolisme;2024-06

4. Antibacterial agents and the fight against antibiotic resistance: A real-world evidence analysis of consumption and spending by an Italian healthcare company;Annales Pharmaceutiques Françaises;2024-05

5. Comparison and Analysis of Antibiotic Consumption in Two Italian Hospital Settings in Relation to the Fight of Antimicrobial Resistance;Pharmaceuticals;2024-01-30